Arthritis News and Research RSS Feed - Arthritis News and Research Twitter

Many people start to feel pain and stiffness in their bodies over time. Sometimes their hands or knees or shoulders get sore and are hard to move and may become swollen. These people may have arthritis. Arthritis may be caused by inflammation of the tissue lining the joints. Some signs of inflammation include redness, heat, pain, and swelling. These problems are telling you that something is wrong. Joints are places where two bones meet, such as your elbow or knee. Over time, in some types of arthritis but not in all, the joints involved can become severely damaged. There are different types of arthritis. In some diseases in which arthritis occurs, other organs, such as your eyes, your chest, or your skin, can also be affected. Some people may worry that arthritis means they won’t be able to work or take care of their children and their family. Others think that you just have to accept things like arthritis.
Scientists identify white blood cells that tumors use to suppress disease-fighting immune system

Scientists identify white blood cells that tumors use to suppress disease-fighting immune system

A study led by St. Jude Children's Research Hospital scientists has identified the population of white blood cells that tumors use to enhance growth and suppress the disease-fighting immune system. [More]
MU researcher developing nano-scale molecules to image, treat different diseases

MU researcher developing nano-scale molecules to image, treat different diseases

Nanomedicine is the medical application of nanotechnology, or the use of microscopic structures to diagnose, image, treat and prevent disease. Current problems in nanomedicine include understanding and anticipating the potentially toxic impact these nanostructures have on the body and the environment once they're released. [More]
Research finding could inspire new ideas for treating type 2 oculocutaneous albinism

Research finding could inspire new ideas for treating type 2 oculocutaneous albinism

Newly published research provides the first demonstration of how a genetic mutation associated with a common form of albinism leads to the lack of melanin pigments that characterizes the condition. [More]
Older adults participating in hospital-based exercise program report less pain, stiffness and fatigue

Older adults participating in hospital-based exercise program report less pain, stiffness and fatigue

It may seem counterintuitive, but exercise can be beneficial for people suffering from arthritis and other muscle and joint conditions. A new study at Hospital for Special Surgery finds that older adults experienced less pain, reduced stiffness and less fatigue after participating in a hospital-based exercise program. [More]
ARA 290 drug reduces neuropathic pain in type 2 diabetic patients

ARA 290 drug reduces neuropathic pain in type 2 diabetic patients

Molecular Medicine, a peer-reviewed biomedical journal published by the Feinstein Institute Press, published the results of a new study reporting clinically significant pain reduction in type 2 diabetic patients. In an exploratory study conducted by Araim Pharmaceuticals, a biotech company developing novel treatments for chronic diseases, investigators also observed improvements in metabolic control in patients administered ARA 290. [More]
TSRI scientists awarded $2.3 million grant to find ways to erase traumatic memories

TSRI scientists awarded $2.3 million grant to find ways to erase traumatic memories

Scientists from the Florida campus of The Scripps Research Institute have been awarded $2.3 million from the Department of Health and Human Services of the National Institutes of Health to better understand how memories are stored in the hopes of eventually being able to treat posttraumatic stress disorder (PTSD) by erasing traumatic memories without altering other, more benign ones. [More]
Novartis announces FDA approval of Signifor LAR for treatment of patients with acromegaly

Novartis announces FDA approval of Signifor LAR for treatment of patients with acromegaly

Novartis announced today that the US Food and Drug Administration has approved Signifor long-acting release (LAR) (pasireotide) for injectable suspension, for intramuscular use, for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. [More]
Crealta publishes review of post-hoc safety analysis completed for Krystexxa

Crealta publishes review of post-hoc safety analysis completed for Krystexxa

Crealta Pharmaceuticals LLC, today announced that the Journal of Clinical Rheumatology published a comprehensive review of a post-hoc safety analysis that was completed for Krystexxa (pegloticase), including data from the two pivotal randomized Phase III trials and one open-label extension trial. [More]
TWi Biotechnology gets approval of Phase II clinical trial protocol for AC-201 CR tablets

TWi Biotechnology gets approval of Phase II clinical trial protocol for AC-201 CR tablets

TWi Pharmaceuticals, Inc. today announced that its fully owned subsidiary, TWi Biotechnology, Inc., has received US FDA and Taiwan FDA approval of a protocol for a Phase II clinical trial of its AC-201 controlled-release (CR) tablets for the indications of high blood uric acid level and gout. [More]
Gout attacks are most common at night

Gout attacks are most common at night

Research, published today, has shown that an acute gout attack is more than twice as likely to occur during the night or early morning hours as during the day. The increased prevalence of gout attacks at night time was observed even after 24 hours with no alcohol and low purine intake. [More]
CUMC researchers devise way to replace torn knee meniscus

CUMC researchers devise way to replace torn knee meniscus

Columbia University Medical Center researchers have devised a way to replace the knee's protective lining, called the meniscus, using a personalized 3D-printed implant, or scaffold, infused with human growth factors that prompt the body to regenerate the lining on its own. [More]
New study reveals how COX-2 inhibitors can increase risk of heart attack in arthritis patients

New study reveals how COX-2 inhibitors can increase risk of heart attack in arthritis patients

A class of drug for treating arthritis - all but shelved over fears about side effects - may be given a new lease of life, following the discovery of a possible way to identify which patients should avoid using it. [More]
Mylan announces U.S. launch of Celecoxib Capsules

Mylan announces U.S. launch of Celecoxib Capsules

Mylan Inc. today announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first available generic versions of Pfizer's Celebrex Capsules, which is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults. [More]
Can-Fite to commence pre-clinical development program of CF602 drug for sexual dysfunction

Can-Fite to commence pre-clinical development program of CF602 drug for sexual dysfunction

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported that it will initiate a pre-clinical development program of its next generation drug CF602 for the indication of sexual dysfunction. Upon successful completion, the company intends to file an IND with the FDA to allow human Phase I studies. [More]
Arthritis drug baricitinib meets primary endpoint in Phase 3 RA-BEACON study

Arthritis drug baricitinib meets primary endpoint in Phase 3 RA-BEACON study

Eli Lilly and Company and Incyte Corporation today announce that the Phase 3 RA-BEACON study of the investigational medicine baricitinib met its primary endpoint of improved ACR20 response compared to placebo after 12 weeks of treatment. [More]
Zydus Cadila becomes world's first company to launch biosimilar of Adalimumab

Zydus Cadila becomes world's first company to launch biosimilar of Adalimumab

After more than a decade-long wait, the revolutionary therapy that provided a new lease of life to millions of patients suffering from rheumatoid arthritis and other auto immune disorders globally will now be accessible to patients in India. Zydus Cadila becomes the first company anywhere in the world to launch the biosimilar of Adalimumab - the world's largest selling therapy. [More]
Alere starts voluntary correction about use of Alere INRatio and INRatio 2 PT/INR Monitor system

Alere starts voluntary correction about use of Alere INRatio and INRatio 2 PT/INR Monitor system

Alere Inc. has initiated a voluntary correction to inform U.S. users of the Alere INRatio and INRatio 2 PT/INR Monitor system of certain medical conditions that should not be tested with the system (INRatio Monitor or INRatio 2 Monitor and INRatio Test Strips). [More]
Study: Key protein may help prevent tumor growth, promote wound healing

Study: Key protein may help prevent tumor growth, promote wound healing

A key protein may represent a new way to use the immune system to speed healing and counter inflammatory, infectious and autoimmune diseases, according to study led by researchers at the Icahn School of Medicine at Mount Sinai and published in the December issue of Cell Reports. [More]
MorphoSys, Xencor announce final results from MOR208 Phase 1/2a trial in patients with CLL/SLL

MorphoSys, Xencor announce final results from MOR208 Phase 1/2a trial in patients with CLL/SLL

MorphoSys AG and Xencor Inc. today announced the publication of final results of a Phase 1/2a trial evaluating MOR208 (formerly XmAb5574) in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL). [More]
BRI signs license agreement with SOBI for Kineret (anakinra)

BRI signs license agreement with SOBI for Kineret (anakinra)

Baylor Research Institute, the research arm of the Baylor Scott & White Health, announced that it has signed an agreement with Swedish Orphan Biovitrum AB (Sobi) to non-exclusively license Baylor's patents pertaining to the treatment of Systemic Onset Juvenile Idiopathic Arthritis (SJIA or SOJIA) using interleukin-1 (IL-1) beta antagonists. [More]